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Abstract
The T box transcription factor TBX2, a master regulator of organogenesis, is aberrantly amplified in aggressive human
epithelial cancers. While it has been shown that overexpression of TBX2 can bypass senescence, a failsafe mechanism
against cancer, its potential role in tumor invasion has remained obscure. Here we demonstrate that TBX2 is a strong cell-
autonomous inducer of the epithelial-mesenchymal transition (EMT), a latent morphogenetic program that is key to tumor
progression from noninvasive to invasive malignant states. Ectopic expression of TBX2 in normal HC11 and MCF10A
mammary epithelial cells was sufficient to induce morphological, molecular, and behavioral changes characteristic of EMT.
These changes included loss of epithelial adhesion and polarity gene (E-cadherin, ß-catenin, ZO1) expression, and abnormal
gain of mesenchymal markers (N-cadherin, Vimentin), as well as increased cell motility and invasion. Conversely, abrogation
of endogenous TBX2 overexpression in the malignant human breast carcinoma cell lines MDA-MB-435 and MDA-MB-157 led
to a restitution of epithelial characteristics with reciprocal loss of mesenchymal markers. Importantly, TBX2 inhibition
abolished tumor cell invasion and the capacity to form lung metastases in a Xenograft mouse model. Meta-analysis of gene
expression in over one thousand primary human breast tumors further showed that high TBX2 expression was significantly
associated with reduced metastasis-free survival in patients, and with tumor subtypes enriched in EMT gene signatures,
consistent with a role of TBX2 in oncogenic EMT. ChIP analysis and cell-based reporter assays further revealed that TBX2
directly represses transcription of E-cadherin, a tumor suppressor gene, whose loss is crucial for malignant tumor
progression. Collectively, our results uncover an unanticipated link between TBX2 deregulation in cancer and the acquisition
of EMT and invasive features of epithelial tumor cells.
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Introduction
The developmentally important transcription factor T box 2
(TBX2) is abnormally amplified with high prevalence in aggressive
human epidermal cancers. TBX2 maps to chromosome 17q23.2,
a region that is aberrantly amplified inover40%ofbreast cancers [1],
40% ofmelanomas [2], 40% of ovarian [3], 56% of endometrial [4],
and 60% of pancreatic cancers [5], correlating with poor clinical
outcome. In breast cancer, TBX2 gene amplification is associated
with invasivehereditaryBRCA1-andBRCA2-relatedcancers, high-
grade-sporadic breast tumors, and distant metastases [6,7,8]. TBX2
is also amplified and overexpressed in several human breast
carcinoma cell lines [6,9,10]. However, the potential role of TBX2
in malignant tumor progression has remained unclear.
TBX2 is a member of the evolutionary conserved T box
transcription factor family [11,12], a class of master regulators of
embryogenesis that share a T box DNA binding domain and
comprise many disease genes [13]. TBX2 acts mainly as a transcrip-
tional repressor [14,15,16] that has been shown to recruit Histone
Deacetylase 1 (HDAC1) to target gene promoters [2]. During
embryogenesis, TBX2 is fundamental to the regulation of cell fate
decisions, cell migration, and morphogenesis in a variety of organs
including the limbs, heart, kidney, nervous system, and eyes
[17,18,19,20,21,22]–albeit throughmechanisms that remainpoorly
understood. TBX2 is also prominently expressed in the embryonic
mammary glandswith a restricted expression inbreastmesenchymal
cells,whichgive rise to the stroma[23,24].Althoughearly embryonic
lethality of Tbx2 knockout mice, due to severe heart defects, has
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precluded analysis of TBX2 function in mammopoiesis [18], adult
heterozygous Tbx2 mouse mutants exhibit mild mammary gland
branchingdefects, suggesting thatTBX2maybe required fornormal
mammary gland morphogenesis [24].
TBX2 is also implicated in cell cycle regulation [9,25], whereby
overexpression of TBX2 in different in vivo model and cell culture
systems has shown to both promote [9,10,21,26], as well as attenuate
cellproliferation[27,28].InappropriateactivationofTBX2incancer
is thought to contribute to early tumor progression by its ability to
over-ride senescence and therefore maintain tumor growth [9].
Senescence is a permanent G1 growth arrest induced by DNA
damage or oncogenic insult that represents a failsafe mechanism
against cancer [29]. TBX2 has been shown to suppress senescence
through both p53-dependent [2,9,15,30] and p53–independent
mechanisms [10,26]. Consequently, TBX2 can cooperate with
transforming oncogenes (c-Myc, Ras) or the loss of tumor suppressor
genes (p53, Rb) in cellular transformation [9,31,32]. Moreover,
overexpression of TBX2 in human lung and skin cancer models,
although inhibitory to cell growth, has been shown to promote the
resistance of tumor cells to the anti-cancer drug cisplatin [28].Whilst
the anti-senescence activity of TBX2 has been extensively studied, it
has remained unclear whether TBX2 can also contribute to tumor
invasion, as the clinical association of TBX2 gene amplification with
invasive epidermal tumors would suggest.
There is increasing evidence that aberrant activation of the
embryonic morphogenetic program, termed the epithelial-mesen-
chymal transition (EMT), is crucially involved in tumor cell
invasion [33]. During EMT, adherent epithelial cells lose polarity,
undergo a major reorganization of the cytoskeleton and acquire
a fibroblastic (mesenchymal), highly motile phenotype [34]. EMT
is potently activated by TGFß [35], and at the transcriptional level
by a growing list of embryonic transcription factors (TFs) [33].
These include the E-cadherin repressing Zinc finger proteins Snail
(SNAI1) and Slug (SNAI2) [36,37], ZEB1 (hEF1) and ZEB2 (SIP1)
[38,39]; the basic helix-loop-helix proteins TWIST1/2 [40,41,42];
the homeodomain proteins Goosecoid, LBX1 and SIX1
[43,44,45]; and the winged-forkhead transcription factor FOXC2
[46]. Virtually all of these TFs have also been implicated as drivers
of oncogenic EMT and breast cancer metastasis [47,48,49,50].
EMT is increasingly viewed as a significant clinical problem in
cancer, as EMT is thought to promote an aggressive cancer stem
cell phenotype [51,52], therapy resistance [53], and tumor
recurrence [54], thereby contributing to poor disease outcome.
Thus, there is an urgent need for the identification and
characterization of the genes involved in this process.
Through ectopic expression of TBX2 in normal mammary
epithelial cells and RNAi-mediated silencing of endogenous TBX2
overexpression in malignant human breast carcinoma cell lines, we
demonstrate that TBX2 acts as a strong cell-autonomous inducer
of EMT. We found that TBX2 directly represses E-cadherin
transcription and promotes malignant tumor progression by
imparting an aggressive mesenchymal tumor phenotype. These
findings, together with a significant correlation between high
TBX2 expression levels in primary tumors and reduced metastasis-
free survival of breast cancer patients, suggest that TBX2 may be
an attractive new target for anti-metastatic cancer therapies.
Results
TBX2 Efficiently Induces EMT in Mammary Epithelial Cells
We were intrigued by previous observations that during mouse
embryonic development, Tbx2 is exclusively expressed in mesen-
chymal cells surrounding the mammary epithelial anlagen [23,24],
suggesting it may regulate mesenchymal cell specification in the
breast. Yet, studies examining TBX2 expression in a small number
of human breast cancers have reported TBX2 mRNA and protein
overexpression primarily in the epithelial compartment of tumors
with little or no expression in stromal cells [7,55]. We therefore
hypothesized that the apparent misexpression of TBX2 in breast
epithelial cells during carcinogenesis may confer mesenchymal
properties to these cells. To test this hypothesis, TBX2 was stably
introduced into murine HC11 and human MCF10A cells, two
spontaneously immortalized but otherwise normal mammary
epithelial cell lines, which we found lack endogenous TBX2
expression (Figure 1B, 1D and Figure S3A, S3B). To avoid clonal
selection bias, several individual polyclonal cell cultures expressing
pCDNA3-TBX2 plasmid (+TBX2) or pCDNA3 vector (+vector)
alone were established. Each of the TBX2-expressing HC11 and
MCF10A cell derivatives (n = 3 per line) showed a dramatic
change in cell morphology from the earliest passages onwards
(Figure 1A, 1C). While vector-transfected HC11 or MCF10A cells
had a typical epithelial cell structure, HC11+TBX2 cells were
abnormally enlarged and stretched out with lamelopodia-like
migratory protrusions (Figure 1A). In addition, MCF10A+TBX2
cells clearly displayed a spindle-shaped, fibroblastoid, and
scattered morphology (Figure 1C). Analysis of EMT marker
protein expression by Western Blot and immunofluorescence
revealed that the TBX2-induced morphologic changes were due to
EMT (Figure 1B, 1D, and 1E). Protein levels of the epithelial
adherence junction proteins E-cadherin and ß-catenin were
decreased in HC11+TBX2 and MCF10A+TBX2 cells, whereas
mesenchymal markers, Vimentin and N-cadherin, were markedly
upregulated as compared to the respective vector control cells
(Figure 1B, 1D, and 1E). Furthermore, whereas in confluent
HC11+vector control cells, E-cadherin, ß-catenin, and the tight
junction protein ZO1 were detected primarily at cell-to-cell
junctions, TBX2-expressing HC11 cells at the same cell density
exhibited a reduced and disrupted immunostaining for these
epithelial cell adhesion molecules at the cell periphery (Figure 1E).
A breakdown of epithelial adhesion complexes was further evident
by a significant reduction in mRNA levels for E-cadherin, ß-catenin,
ZO1, and the desmosomal component Desmoplakin by 50–70%
respectively in TBX2-overexpressing HC11 cells as determined by
quantitative realtime PCR (qPCR) (Figure 1F). Of mesenchymal
markers analyzed, N-cadherin, and the extracellular matrix
metalloproteinase Mmp3 were most significantly upregulated in
these cells (Figure 1F). A similar switch from epithelial to
mesenchymal marker gene expression was also evident in
MCF10A+TBX2 cells (Figure S1A, S1B). Thus, TBX2 efficiently
induced morphologic and molecular changes characteristic of
EMT in mammary epithelial cells.
TBX2 Promotes Mammary Epithelial Cell Motility and
Invasiveness
We next tested whether ectopic expression of TBX2 promotes
any behavioral changes associated with EMT, such as increased
motility and gain of invasiveness. Parental and vector-expressing
HC11 or MCF10A cells have a low propensity to migrate and
invade extracellular matrix (Figure 2). However, both TBX2-
overexpressing HC11 and MCF10A cells exhibited a significant
increase in cell motility in ‘‘in vitro scratch’’ assays, which was
visible as early as 4–8 hours after an experimentally induced
wound and became more pronounced between 8–32 hours,
leading to a complete wound closure by MCF10A+TBX2 cells
at 24 hours (Figure 2A, 2B). The increased movement of TBX2-
expressing mammary epithelial cells was not due to increased
proliferation since the assay was done in low serum-containing
medium (see Methods), in which these cells were growth-retarded
TBX2, a New EMT Inducer in Breast Cancer
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Figure 1. TBX2 induces epithelial-mesenchymal transition (EMT) in breast epithelial cells. (A) Bright field images (40x magnification) of
murine HC11 mammary epithelial cells stably transfected with pCDNA3 (+vector) or pCDNA3-TBX2 (+TBX2) expression plasmids showing
morphological changes in TBX2-expressing HC11. (B) Western blot analysis using whole cell lysates from HC11+vector and HC11+TBX2 cells shows
TBX2-induced downregulation of epithelial (Epi) and upregulation of mesenchymal (Mes) marker proteins. E-cad = E-cadherin; ß-cat = ß-catenin; N-
cad = N-cadherin; Vim = Vimentin. Actin (ß-actin) was used as loading control. Fold changes in protein levels quantified by densitometry and
normalized to Actin values are shown. (C) Bright field images (40X magnification) of human MCF10A mammary epithelial cells stably expressing
pCDNA3 or pCDNA3-TBX2 reveal mesenchymal transformation of MCF10A+TBX2 cells. (D) Western Blot analysis shows that ectopic expression of
TBX2 in MCF10A cells prompts a switch of EMT marker expression. (E) Immunofluorescence analysis of TBX2 (red) and EMT marker expression (40X
magnification) shows loss of membrane-associated expression of epithelial (green) with a reciprocal gain of mesenchymal (red) marker expression in
HC11+TBX2 cells as compared to HC11+vector control cells. Nuclei were stained with Hoechst 33258 (blue). (F) qPCR analysis comparing Tbx2 and
EMT marker expression in HC11+vector and HC11+TBX2 cells. E-cad = E-cadherin; ß-cat = ß-catenin; ZO1= zona occludens 1; Dsp = Desmoplakin; N-
cad = N-cadherin; Mmp3= matrix metalloprotease 3. Values were normalized to Gapdh. Fold changes as compared to vector control cells are shown.
Error bars represent the mean 6 SEM (n= 3; Student t-test). P values are indicated.
doi:10.1371/journal.pone.0041355.g001
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(data not shown). To examine the role of TBX2 in the regulation
of cell invasiveness, we performed Transwell matrigel invasion
assays (Figure 2C, 2D). Both TBX2-expressing HC11 and
MCF10A cells, showed an approximately four-fold increase in
their abilities to invade through the matrigel layer towards serum-
containing media (Figure 2C, 2D). Thus, TBX2 plays a central
role in the acquisition of cell motility and invasiveness of breast
epithelial cells through induction of EMT.
TBX2 is Induced during TGFß-mediated EMT of Primary
Human Mammary Epithelial Cells
We further examined expression of endogenous TBX2 in
a cellular model of inducible EMT. We have previously shown
that treatment of primary finite-lifespan human mammary
epithelial cells (HMEC) with the cytokine TGFß efficiently induces
EMT, as well as a hierarchy of known EMT-associated
transcription factors [56]. While TBX2 was not expressed in
untreated HMEC (Figure 3A and 3C), both TBX2 mRNA and
protein were upregulated upon EMT induction by TGFß
coinciding with a decrease in epithelial and acquisition of
mesenchymal marker expression (Figure 3A–3C). A significant
induction of TBX2 mRNA expression occurred as early as 6 hours
(,1.8 fold; p,0.001) upon TGFß stimulation and further
increased to 3.3–4.3 fold by 9–12 days (p,0.001) (Figure 3B).
Notably, the rapid increase of TBX2 mRNA levels, accompanied
by a reduction in epithelial E-cadherin and an increase in
mesenchymal Vimentin mRNA expression (Figure 3B), occurred
well before any morphological changes of EMT became visible at
3 days of TGFß treatment [56]. Moreover, TBX2 protein
specifically localized to the nucleus of TGFß-treated HMEC
(Figure 3A), where it is thought to be active as a transcription
factor. These data indicate that TBX2 is also part of the
endogenous EMT program of primary HMEC and further
implicate TBX2 in EMT induction of breast epithelial cells.
TBX2 Expression in Human Breast Tumors Correlates with
EMT Features and Increased Disease Recurrence
EMT and increased invasiveness are key features of epithelial
tumor cells as they progress into malignant metastatic cancer cells
[33]. We therefore asked whether the EMT-inducing and pro-
invasive abilities of TBX2 that we observed in normal breast
epithelial cells, could also play a role in human breast cancer.
Since little is known about TBX2 expression in human breast
tumors, we performed a comprehensive meta-analysis of TBX2
Figure 2. TBX2 promotes migration and invasion of mammary epithelial cells. (A, B) In vitro ‘scratch’ assays (see Methods) monitoring the
migration of (A) murine HC11 and (B) human MCF10A cells stably expressing pCDNA3 vector (+vector) or pCDNA3-TBX2 (+TBX2) over a period of 24–
32 hours (h). Representative bright field images of cells (10x magnification) are shown in the left panel. Right panel: statistical evaluation of the
distance between the two borders (dotted lines; left panels) at different time points after ‘scratch’ (n = 3; ANOVA test). (C, D) Transwell matrigel
invasion assays show a significantly increased ability of TBX2-expressing HC11 (C) and MCF10A cells (D) to invade through a matrigel layer (n = 3,
Student’s t-test). The mean 6 S.D. is shown. P values are indicated.
doi:10.1371/journal.pone.0041355.g002
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expression using an integrated gene expression database that
encompassed 1107 primary human breast tumors from six
published datasets [57]. We found that TBX2 was variably
expressed across the different molecular subtypes of breast cancer
[58] (Figure S2A), largely independent of estrogen receptor (ER)
status and tumor grade (Figure S2B, S2C), with the highest
expression levels among the rare, aggressive ‘claudin-low’ subtype
of breast cancer and lowest in basal tumors (Figure S2A).
Interestingly, the ‘claudin-low’ subtype of breast tumors has
recently been shown to be enriched for EMT features [59,60].
Another dataset showed that TBX2 was higher in poor prognosis
metaplastic breast cancers (Figure S2D), which like the ‘claudin-
low’ group exhibit an EMT gene signature and are highly
metastatic [60,61]. Expression of TBX2 was not significantly
higher in the ‘claudin-low’ tumors of this dataset, but the numbers
of tumors (n = 13) were much lower than in the in the ‘six study’
analysis (n = 34) [57].
A similar tumor subtype distribution of TBX2 overexpression
was observed in a panel of a total of 20 human breast carcinoma
cell lines using Western blot and qPCR analyses (Figures S3 and
S4). We confirmed endogenous TBX2 overexpression in three
ER-positive luminal tumor lines (MCF7, MDA-MB361, and BT-
474) (Figure S3A–C) that have previously been shown to harbor
TBX2 gene amplifications [6,9,10]. Moreover, the ER-negative
basal breast carcinoma cell line SUM52 [62] displayed abundant
TBX2 protein and mRNA expression, as well as modest gene
amplification levels (Figure S3A–3C), consistent with previous
Fluorescence In Situ Hybridization (FISH) data [6]. In addition, we
identified TBX2 overexpression in two metaplastic tumor-derived
breast carcinoma cell lines, MDA-MB-435 and MDA-MB-157
[63,64], which we found to express higher median levels of TBX2
than most other breast tumors (Figure S2D). Both of these cell lines
exhibit mesenchymal gene signatures [64], and have an increased
invasive, metastatic potential [63,65]. Comparative genomic
hybridization array (aCGH) analysis showed no significant
increases in TBX2 gene copy numbers in MDA-MB-435 and
MDA-MB-157 (Figure S3C), suggesting that overexpression of
TBX2 in these tumor cell lines is not due to gene amplification.
TBX2 gene amplification has previously been reported in
aggressive BRCA1-related breast cancers [6,7]. However none of
the four basal-subtype ER-negative BRCA1-deficient breast
carcinoma cell lines (HCC1937, MDA-MB-436, SUM149, and
SUM1315) we studied expressed TBX2 protein at detectable levels
or exhibited TBX2 gene amplification (Figure S4A, S4B).
Furthermore, TBX2 was not expressed in any normal-derived
human breast epithelial cell line (Figures S3 and 1B, 1D).
The prognostic significance of TBX2 in human breast cancer
was examined next by meta-analysis. High TBX2 transcript levels
were found to be significantly associated with a shorter time to
recurrence-free survival (Figure 4A, 4B). This was more significant
Figure 3. Endogenous TBX2 is induced during TGFß-mediated EMT of primary human mammary epithelial cells (HMEC). (A) Bright
field (40x magnification) and immunofluorescence images (63X magnification) of primary HMEC treated with 5 ng/ml TGFß1 (+TGFß) for 12 days as
compared to untreated control cells (-TGFß). TGFß induces EMT-like morphological changes and nuclear expression of TBX2 (red). Nuclei were stained
with Hoechst 33258 (blue). (B) qPCR analysis shows a time course analysis of TBX2 mRNA induction in TGFß–treated HMEC in comparison to changes
in epithelial E-cadherin (E-cad) and mesenchymal Vimentin (Vim) expression. Values were normalized to GAPDH mRNA and represent fold changes as
compared to control untreated HMEC at the indicated time points. Error bars represent SEM of each sample in triplicates. (C) Western blot analysis of
TBX2 and EMT marker expression in untreated HMEC (2) and in HMEC treated with TGFß for 12 days. E-cad = E-cadherin; ß-cat = ß-catenin; Vim =
Vimentin; N-cad = N-cadherin; Epi = epithelial; Mes = mesenchymal markers. Actin = ß-actin was used as loading control. Densitometric
quantification of fold changes in protein levels normalized to Actin values is shown.
doi:10.1371/journal.pone.0041355.g003
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for ER-positive tumors and similar results were seen in the
completely independent 295-sample NKI dataset [66] (Figure 4A,
4B). Overall, these results are compatible with the notion that
TBX2 is activated in certain primary breast cancers correlating
with an EMT signature and reduced metastasis-free survival.
Silencing of TBX2 Leads to Mesenchymal-epithelial-
transition and Impedes the Invasiveness of Human Breast
Cancer Cells
To elucidate the potential role of TBX2 in malignant tumor
progression, we employed RNA interference strategies to inhibit
TBX2 in the metastatic breast carcinoma cell lines MDA-MB-435
and MDA-MB-157 (Figures 5 and 6). Efficient TBX2 knockdown
was achieved in MDA-MB-435 tumor cells by stable transduction
with lentiviruses expressing TBX2-specific shRNA (shTBX2), and
in MDA-MB-157 cells by transient transfection with TBX2-
specific siRNAs (siTBX2) (Figure 5A, 5D and 5E). Notably,
whereas MDA-MB-435 cells transduced with control non-target
shRNA (shCtrl), or MDA-MB-157 cells transiently transfected
with control scrambled siRNAs (siCtrl), had a fibroblastoid
‘spindle-like’ appearance similar to the respective parental cell
lines, TBX2-depleted MDA-MB-435 and MDA-MBA-157 tumor
cells displayed a ‘cobblestone-like’’ epithelial morphology (Fig-
ure 5B, 5C). Concordant with this phenotype, mRNA expression
Figure 4. TBX2 overexpression in primary human breast tumors is correlated with reduced metastasis-free survival. Kaplan Meier
analysis demonstrates that TBX2 mRNA overexpression is associated with shortened recurrence-free survival (A) in a meta-analysis of six combined
published microarray datasets comprising 1107 primary human breast tumors [57], and (B) in an NKI study of 295 women with early-stage invasive
breast carcinomas [66]. In both of these datasets, the optimal cut-point value of TBX2 expression was used to divide the samples into high (above
median; green) and low (below median; blue) TBX2 expression. A batch correction was performed on the six-study set (see Methods). High TBX2
expression is particularly associated with poor prognosis in estrogen receptor-positive (ER+) breast tumors (right panels). ER status was determined
by immunohistochemistry (IHC). P values are indicated.
doi:10.1371/journal.pone.0041355.g004
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of epithelial E-cadherin and ZO1 was enhanced, whereas transcrip-
tion of mesenchymal genes (N-cadherin, Vimentin, Fibronectin, MMP3)
was reduced in TBX2-depleted MDA-MB-435 and MDA-MB-
157 breast cancer cells (Figure 5D, 5E). Immunofluorescence
analysis further confirmed that TBX2 inhibition resulted in the re-
expression of E-cadherin protein in MDA-MB-435 cells, which
are normally devoid of this epithelial marker (Figure 5F) [35].
Moreover, epithelial ß-catenin and ZO1 not only were increased
in levels, but also properly localized to the cell membrane in
TBX2-depleted MDA-MB-435 tumor cells (Figure 5F). In
contrast, mesenchymal markers (N-cadherin, Vimentin) were
drastically reduced and, for N-cadherin, mislocalized to the
cytoplasm in MDA-MB-435-TBX2 knockdown cells (Figure 5F).
Inhibition of TBX2 further led to reduced tumor cell migration
in both MDA-MB-435 and MDA-MB-157 breast carcinoma cell
lines (Figure 6A, 6B). Moreover, tumor cell invasion rates in
Transwell matrigel invasion assays were markedly decreased
(Figure 6D, 6E). Additionally, whereas control non-target shRNA
expressing MDA-MB-435 tumor cells formed spheroids with
extensive protrusions in three-dimensional (3D) Matrigel cultures,
reflective of their invasive nature, knockdown of TBX2 resulted in
the formation of round, non-invasive spheres (Figure 6C). Thus,
loss of TBX2 in malignant breast carcinoma cells abolished tumor
cell invasion and lead to the restitution of a more differentiated
epithelial phenotype. All experiments were done with at least two
independent cell clones from each stably shRNA transfected cell
line and three independent polyclonal cultures of cell lines
transiently transfected with siRNAs.
TBX2 is Crucial for Metastasis of Breast Carcinoma Cells
To further investigate how aberrant overexpression of TBX2
contributes to malignant tumor progression, we analyzed the
metastatic potential of TBX2-depleted MDA-MB-435 tumor cells.
MDA-MB-435 cells expressing either shCtrl or shTBX2 were
injected into the tail veins of immunocompromised nu/nu Nude
mice. Lung colonization was assessed 40 days post tumor cell
transplantation. Functional inhibition of TBX2 in MDA-MB-435
(two independent clones: shTBX2 C2 and shTBX2 C4) led to
a strong reduction in the number of lung nodules and
micrometastases as compared to MDA-MB-435+shCtrl cells
(Figure 7A, 7B). Growth rates were not significantly reduced for
shTBX2 expressing MDA-MB-435 tumor cells in culture
(Figure 7C). Moreover, mRNA expression of the cell cycle
inhibitor p21CIP1/WAF1, which is a direct transcriptional target of
TBX2 in senescence bypass [2,30], was not significantly altered in
TBX2 knockdown cells (Figure 7D), nor did these cells exhibit any
signs of senescence (data not shown). These data suggest that
TBX2 is crucial for the formation of metastases independent of
effects on tumor cell growth. Taken together, our TBX2 inhibition
studies in malignant breast carcinoma cell lines reinforce the
notion that TBX2 promotes malignant tumor progression by
imparting a highly invasive mesenchymal phenotype on breast
epithelial tumor cells.
TBX2 Represses E-cadherin Transcription
Loss of E-cadherin is an important hallmark of EMT, directly
contributing to transformation and metastatic tumor progression
[67,68]. Studies in melanoma cells have raised the possibility that
TBX2 may be implicated in E-cadherin regulation, but failed to
detect a requirement of TBX2 for E-cadherin expression in vivo [69].
Since we found overexpression of TBX2 to consistently reduce
endogenous E-cadherin levels in normal mammary epithelial cells,
and, conversely, inhibition of TBX2 to lead to enhanced E-cadherin
mRNA expression in metastatic breast cancer cell lines (Table 1,
Figures 1F and 5D, 5E), we revisited the question whether TBX2
could directly repress E-cadherin at the promoter level.
Chromatin immunoprecipitation (ChIP) analysis was performed
to determine direct in vivo binding of TBX2 to the endogenous E-
cadherin gene in mammary epithelial cells (Figure 8A, 8B). We used
three different primer sets; one covering the most proximal
promoter region of E-cadherin, including the initiator element (InR:
TGGTGT in mouse and AGTGGC in human at +1 to +6 each),
which has previously been shown to be bound by a recombinant
TBX2 DNA binding domain in vitro [69]; one set spanning
a conserved half T-box factor binding site (Half T-site:
AGGTGTTA at 2682 in mouse and TCACACCT at 2645 in
human) [69]; and one primer set in a distal region (21299/
21119) devoid of potential TBX2 binding sites (Figure 8A). PCR
amplification of these genomic sequences using immunoprecipi-
tated chromatin from HC11+vector or HC11+TBX2 cells
demonstrated that TBX2 specifically bound to the proximal E-
cadherin promoter (Figure 8B), which contains the InR element
(Figure 8A) that can serve as a putative TBX2-binding site [15,69].
To test the functional significance of in vivo TBX2 occupancy of
this E-cadherin promoter region, we transiently co-transfected
HC11 cells with a luciferase reporter construct (pEcad-luc)
containing the proximal human E-cadherin promoter (2108 to
+125) [70] and with increasing concentrations of pCDNA3-TBX2
expression plasmid (Figure 8C). As compared to empty vector
control (basal), co-expression of TBX2 led to a significant (p,0.05)
3.7 fold reduction in the activity of this promoter in a dose-
dependent manner. Together, these results indicated that TBX2
directly represses transcription of E-cadherin by binding to its
proximal promoter in vivo.
Discussion
In this study, we have identified the embryonic transcriptional
repressor and anti-senescence factor TBX2 as a novel potent
inducer of EMT that directly represses E-cadherin transcription and
promotes an aggressive, mesenchymal breast tumor phenotype
(Figure 9). Since TBX2 is aberrantly amplified with high
prevalence in a number of aggressive human epidermal cancers,
or, as we found, can be induced by TGFß (Figure 9), a promoter of
metastatic tumor progression [35], these findings are of potential
high clinical relevance. Unlike other EMT-inducing TFs [33],
TBX2 has not previously been implicated in the cell-autonomous
regulation of EMT induction during embryogenesis. Our results
therefore uncover a novel paradigm of TBX2 function that may
also be relevant for its role in normal development.
During embryogenesis, TBX2 is expressed after gastrulation
[11,23], and among other roles, controls mesenchymal cell
specification in the limb buds underlying posterior digit identity
[17], specification and morphogenesis of mesoderm-derived
cardiomyocytes in the valve forming regions of the heart
[18,71], pro-mesonephros identity during kidney development
[19], and cell migration processes during brain and eye
morphogenesis [20,22]. However, the consequences of inappro-
priate gain-of-function of this morphogenetic TF in epithelial
tumor cells during carcinogenesis have been poorly explored. By
modeling aberrant gain-of-function of TBX2 in breast cancer
through ectopic expression of TBX2 in non-malignant mammary
epithelial cell lines (HC11, MCF10A), we demonstrated that
TBX2 alone is sufficient to induce EMT and cell invasion.
Since EMT has been implicated in tumor recurrence [53,54],
and we found high levels of TBX2 expression to be significantly
correlated with disease recurrence in a meta-analysis of over 1,000
primary human breast tumors (Figure 4), we further investigated
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Figure 5. TBX2 imparts a mesenchymal phenotype on human breast cancer cells. (A) Western blot analysis shows efficient TBX2
knockdown in human MDA-MBA-435 tumor cells stably expressing TBX2-specific shRNA (shTBX2) as compared to cells expressing non-target shRNA
(shCtrl). Actin was used as loading control. (B) Depletion of TBX2 in MDA-MB-435 tumor cells leads to a loss of the mesenchymal morphology
characteristic for this breast carcinoma cell line. Representative images of high-density cell cultures are shown (40X magnification). (C) Inhibition of
TBX2 in human MDA-MB-157 breast carcinoma cells through transient transfection with TBX2-targeted siRNAs (siTBX2) induces a ‘cobblestone’-like
epithelial cell morphology. In contrast, MDA-MB-157 cells transiently transfected with scrambled siRNA control (siCtrl) exhibit a profound ‘spindle-like’
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whether the EMT-inducing ability of TBX2 could play a role in
malignant tumor progression. Congruent with our TBX2 over-
expression results in normal breast epithelial cells, RNAi-mediated
silencing of TBX2 in two aggressive mesenchymal human breast
carcinoma cell lines with endogenous TBX2 overexpression
(MDA-MB-435, MDA-MB-157) led to the restitution of a differ-
entiated epithelial tumor phenotype. This was most evident by re-
expression of E-cadherin, ß-catenin, and ZO1, and the concom-
itant loss of mesenchymal N-cadherin, Vimentin, and Fibronectin
expression (Figure 5). Importantly, we found that inhibition of
TBX2 also abolished tumor cell migration, invasion and pro-
foundly diminished the capacity of MDA-MB-435 cancer cells to
form pulmonary metastases in a xenograft in vivo mouse model.
These effects appeared to be independent of the anti-senescence
activity of TBX2, as cell proliferation and expression of the growth
control gene p21CIP1/WAF1 were unchanged in MDA-MB-435-
shTBX2 cells (Figure 7). The observed pro-invasive activity of
TBX2 was likely due to specific induction of MMP3, which unlike
other matrix metalloproteases (MMP2, MMP9) was most consis-
tently upregulated by TBX2 in our cellular systems (Figures 1, 4,
S1; data not shown). Together, these results suggest that TBX2 is
strongly implicated in malignant tumor progression by promoting
an aggressive mesenchymal tumor phenotype.
Interestingly, we found that TBX2 is induced by the EMT-
promoting cytokine TGFß, which is often excessively produced by
invasive breast cancer cells and has been associated with metastatic
tumor progression [35]. Because of the rapid kinetics of TBX2
induction in HMEC upon TGFß treatment, it is tempting to
mesenchymal phenotype. Representative images of high-density cultures (40x magnification) of tumor cells three days post siRNA transfection are
shown. (D, E) qPCR analysis of TBX2 and EMT marker expression in (D) MDA-MB-435 cells expressing shCtrl or shTBX2, and in (E) MDA-MB-157 cells
3 days post transfection with siCtrl or siTBX2. TBX2 knockdown leads to an upregulation of epithelial adhesion and tight junction genes (E-cad = E-
cadherin; ZO1= zona occludens 1), whereas it results in loss of mesenchymal marker expression: N-cad = N-cadherin; VIM = Vimentin; FN1 =
Fibronectin, and MMP3= matrix metalloprotease 3. Values were normalized to GAPDH and fold changes compared to the respective control groups
are shown. Data represent the mean 6 SEM (n= 3; Student t-test); p-values: *p,0.05; **p= 0.003; ***p,0.001. (F) Immunofluorescence analysis (40X
magnification) confirms the re-expression of epithelial (green) E-cadherin, ß-catenin, and ZO1, and the loss and/or mislocalization of mesenchymal
(red) markers (N-cadherin, Vimentin) in TBX2-depleted MDA-MB-435 cells. Nuclei were stained with Hoechst 33258 (blue).
doi:10.1371/journal.pone.0041355.g005
Figure 6. Knockdown of TBX2 in metastatic human breast cancer cell lines abrogates tumor cell invasion. (A, B) Inhibition of TBX2
significantly reduces cell motility rates of (A) MDA-MB-435 tumor cells in in vitro scratch assays, and (B) of MDA-MB-157 breast cancer cells in
Transwell migration assays (see Methods). Data represent the mean 6 S.D. (n = 3; ANOVA test). (C) MDA-MB-435 cells stably expressing TBX2-specific
shRNA (+shTBX2) grow as non-invasive spheres in three-dimensional (3D) Matrigel, whereas MDA-MB-435 control tumor cells expressing non-target
shRNA (+shCtrl) grow as spheroids that invade the surrounding extracellular matrix. (D, E) Transwell matrigel assays showing that knockdown of TBX2
significantly reduces invasion rates of (D) MDA-MB-435, and (E) MDA-MB-157 breast tumor cells. Data represent mean6 S.D. (n = 3; Student’s t-test). P
values are indicated.
doi:10.1371/journal.pone.0041355.g006
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speculate that TGFß signaling controls TBX2 expression at the
transcriptional level. This notion is further supported by studies
demonstrating that BMPs, which are TGFß homologues,
positively regulate Tbx2 expression during cardiogenesis via
functional SMAD binding sites in the Tbx2 gene promoter [72].
Thus, apart from chromosome 17q23 amplification, TBX2
induction by TGFß may represent a novel mechanism underlying
the aberrant overexpression of TBX2 in invasive cancers (Figure 9).
Through ChIP analysis and cell-based promoter-reporter
assays, we further demonstrate that TBX2 binds directly to and
represses the activity of the proximal E-cadherin promoter, in-
dicating that E-cadherin is a direct TBX2 target gene. Given that E-
cadherin acts as a tumor suppressor, whose loss is causally
implicated in EMT and metastatic tumor progression [67,68],
transcriptional repression of E-cadherin by TBX2 may provide
a possible mechanistic explanation for the observed EMT-
inducing and pro-metastatic activities of TBX2 in breast cancer
cells. We note that there was little correlation between TBX2
expression and E-cadherin status in established breast cancer cell
lines (Figure S3) [90], a finding, which has also been reported for
the EMT-inducing transcription factor LBX1 [44]. This could
suggest that efficient repression of E-cadherin by TBX2 might
require cooperation with other transcriptional repressors that may
not be present in all TBX2-overexpressing breast tumor cell lines.
Moreover, established tumor cell lines do not necessarily reflect
the situation in primary breast tumors, in which EMT is
histopathologically difficult to detect due to its transient nature
[73].
Figure 7. Knockdown of TBX2 reduces pulmonary metastasis of human MDA-MB-435 breast carcinoma cells. (A) Representative
images of lungs harvested from athymic nu/nu Nude mice forty days after tail vein injection with MDA-MB-435 tumor cell clones expressing either
control non-target shRNA (shCtrl) or TBX2-specific shRNA (shTBX2). Top panel: India ink staining of lungs shows the absence of surface lung
metastases in mice injected with shTBX2-expressing MDA-MBA-435 tumor cells (Magnification 7x). Only the control group produced macroscopic
lung nodules (asterixes) and an elevated number of micrometastases (white arrows). Bottom panel: H&E stained paraffin-sections of representative
lungs from each study group (Magnification: 40X). Dotted lines highlight lung metastases in the control group. (B) Quantification of total lung
metastasis burden in the same sets of mice as in (A). Average numbers of lung surface metastases are shown; white column = mean of 5 control
mice analyzed: black column = mean of 10 mice injected with two MDA-MB435-shTBX2 tumor cell clones. Data represent the mean 6 S.D. (n$5;
Student t-test). (C) Inhibition of TBX2 does not significantly affect cell proliferation of MDA-MB-435 tumor cells. Equal numbers of control non-target
shRNA and shTBX2-expressing cells were grown under sub-confluent conditions and counted every 3 days over a 9-day period. Error bars represent
the mean 6 S.D. (n = 3; Student t-test). (D) qPCR showing that stable knockdown of TBX2 does not significantly alter p21 mRNA expression levels in
MDA-MB-435 tumor cells. Values were normalized to GAPDH and fold changes compared to the shRNA control group are shown. Error bars represent
the mean 6 SEM (n= 3; Student t-test). NS = not significant.
doi:10.1371/journal.pone.0041355.g007
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In discrepancy with our results, previous studies have indicated
that TBX2 knockdown in MCF7 breast carcinoma and human
melanoma cell models did not diminish tumor cell invasion
[69,74] or repress endogenous E-cadherin expression [69]. Howev-
er, TBX3, a close TBX2 homolog with similar oncogenic
functions [75] not yet implicated in EMT regulation, exerted
these effects in both of those systems [69,74]. A possible
explanation for these conflicting results could be that invasion of
the inherently low-invasive MCF7 cell line in the previous study
was induced by phorbol esters [74], which might have altered
Table 1. Overexpression of TBX2 in normal breast epithelial cell lines results in reduced expression of E-cadherin and knockdown
of TBX2 in breast carcinoma cell lines leads to an increase of E-cadherin expression.
Cell line Percentage relative mRNA expression (TBX2)
Percentage relative mRNA expression
(E-cadherin)
HC11+vector 100 100
HC11+TBX2 3882 30
MCF10A+vector 100 100
MCF10A+TBX2 305 64
MDA-MB-435+shCtrl 100 100
MDA-MB-435+shTBX2 3 226
MDA-MB-157+siCtrl 100 100
MDA-MB-157+siTBX2 14 207
doi:10.1371/journal.pone.0041355.t001
Figure 8. TBX2 bind to the E-cadherin promoter in vivo and represses E-cadherin transcription. (A) Schematic of the E-cadherin/CDH1
promoter depicting the location of potential TBX2 binding sites [10]: half T-site (black box) and InR = Initiator element (hatched box), and of ChIP
primers used in (B). (B) ChIP analysis shows in vivo binding of exogenous TBX2 to the most proximal region of the endogenous E-cadherin gene
promoter in HC11 mammary epithelial cells. DNA derived from sheared chromatin fragments from HC11+vector and HC11+TBX2 was
immunoprecipitated with two antibodies specific to TBX2 (#1 = Millipore AB4147; #2 = SC-17880x), an antibody specific to acetyl Histone 3, or
normal rabbit IgG and quantified by semi-quantitative PCR. As a control,,1% of input chromatin was used in the PCR analysis. The bar graph on the
bottom panel shows a quantification of the TBX2-specific ChIPs for the proximal (2131/+61) E-cadherin promoter as a function of the percentage of
input chromatin. (C) Transient reporter assays of HC11 cells transiently co-transfected with a human E-Cadherin promoter (2108 to +125) luciferase
reporter construct (pEcad-luc) in combination with pCDNA3 vector (basal) or increasing concentrations of pCDNA3-TBX2 (+TBX2), as indicated. One
representative experiment of n = 3 biological replicates is shown; P-value: *p,0.05 (triplicate samples; Student t-test).
doi:10.1371/journal.pone.0041355.g008
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cellular signaling involved in TBX2-mediated EMT induction.
Alternatively, there could be cell-type specific differences in the
activities of TBX2 and TBX3 that may depend on phosphory-
lation status or the differential availability of protein partners.
TBX2 has been shown to be phosphorylated by external stimuli
that alters its cellular localization and, thereby, its activity as
a transcription factor [12]. Furthermore, senescence suppression
by TBX2 in human cells depends on the physical interaction of
TBX2 with tumor suppressive TFs, for example EGR1 in breast
cancer cells [10], and PML in fibroblasts [26]. Interestingly, recent
studies have indicated that transcriptional repression of the
senescence-associated tumor suppressor p14ARF by TBX2
[9,15], requires the association of TBX2 with NRAGE, a protein
that is released from the cell membrane upon EMT induction
[76]. To rule out the possibility that TBX3, which is primarily
overexpressed in luminal E-cadherin-positive breast cancer lines
and estrogen receptor-positive breast tumors [77,78], contributed
to the pro-invasive effects elicited by TBX2, we investigated TBX3
expression in our TBX2-dependent breast epithelial model
systems (Figure S5). We found a reciprocal expression of these
T-box factors, with TBX3 downregulated in TBX2-expressing
HC11 cells but upregulated in TBX2-depleted HC11+TBX2 and
MDA-MB-435 tumor cells (Figure S5A, S5B), which is reminiscent
of the mutually exclusive expression patterns of TBX2/3 in
normal mammary gland tissues [23,79], Thus, the TBX2-induced
EMT phenotypes were not due to a possible interference by TBX3
but rather may reflect the poorly explored role of TBX2 as
a mesenchymal and baso-myoepithelial transcription factor in
breast development [23,24]. In contrast, TBX3 functions as
a master regulator of mammary epithelial cell fate [80,81], and in
the adult breast is specifically expressed in differentiated luminal
breast epithelial cells [79].
Significantly, a role of TBX2 in oncogenic EMT and malignant
breast cancer progression is further suggested by our finding that
TBX2 mRNA levels in clinical human breast cancer specimen
were highest in rare EMT-enriched tumors of the ‘claudin-low’
and metaplastic breast tumor subtypes. These tumors represent
one of the most aggressive and treatment-resistant forms of breast
cancer [59,60,61]. Moreover, we found high TBX2 transcript
levels to be significantly associated with reduced metastasis-free
survival of breast cancer patients, which is in keeping with the
correlation of TBX2 gene amplification data with poor clinical
outcome [6,8]. Since tumor tissues used for expression profiling
are subjected to histology and only included if they contain
a reasonable percentage of tumor cells it is unlikely that the
observed correlations are due to expression of TBX2 in tumor
associated stroma. It was perhaps surprising that TBX2 expression
was predictive of poor prognosis but independent of ER status and
that basal subtype and high-grade breast tumors had slightly lower
average levels of TBX2 expression (Figure S2). However, these
findings are consistent with TBX2 having a similar pattern of gene
expression across subtypes as other EMT-inducing TFs, e.g. Twist,
ZEB1, ZEB2, and SNAI2 (Slug) [60]. Furthermore, recent clinical
population studies have shown that even breast tumors in the
lowest risk category (ER+, early stage, small tumor size, node-
negativity) and despite adjuvant treatment can have relatively high
relapse rates [82,83]. Thus, TBX2 may prove to have a unique
value as a novel prognostic marker.
Collectively, our work suggests that TBX2 is a key driver of
malignant tumor progression through induction of EMT and
tumor cell invasiveness. Although previous mouse developmental
genetic studies have indicated that TBX2 can indirectly promote
EMT of endocardial cells during cardiac valve formation through
induction of paracrine TGFß2 signaling in surrounding valve-
forming myocardium [72], our work is the first to demonstrate that
TBX2 can also activate EMT in a cell-autonomous manner.
Further experiments are under way to identify the signaling
mechanisms, potential interacting partners, and target genes of
TBX2 in EMT induction and epithelial tumor invasion. Finally,
our discovery that TBX2, an established anti-senescence factor, is
a strong inducer of EMT lends further support to the notion that
EMT and senescence bypass may rely on some of the same
molecular mechanisms [41,42]. We anticipate our studies to be
a starting point for evaluating TBX2 as a new marker for breast
cancer diagnosis and potential target for anti-metastatic cancer
drug development.
Methods
Ethics Statement
All experiments including the use of mice were approved by the
University of Miami IACUC (protocol number 10–226, In-
stitutional assurance number for the University of Miami A-3224-
01). For the studies we describe, there are no suitable alternative
approaches, and care was taken to minimize animal distress.
Cell Lines
The HC11 mouse mammary epithelial cell line [84] (kindly
provided by Dr. Kermit Carraway, University of Miami) was
grown in complete growth medium (RPMI containing 10% FBS,
1% penicillin-streptomycin, 1 mg/ml EGF (Invitrogen) and 5 mg/
ml insulin (Sigma-Aldrich). Human MCF10A mammary epithelial
cells were obtained from the American Type Cell Collection
(ATCC) and grown in HuMEC medium (Invitrogen). Linearized
pCDNA3 or pCDNA3-TBX2 expression plasmids [85] (kindly
provided by Dr. Roni Bollag, Medical College of Georgia,
Augusta, GA, USA) were introduced into cells by Lipofectamin
2000 transfection (Invitrogen) and stable transfectants were
selected in 200–300 mg/ml G418 for 9–11 days. Primary HMEC
were from Cambrex Bio Science and cultured in HuMEC
medium. TGFß induction experiments using 5 ng/ml of recom-
binant TGFß1 (R&D Systems) were performed as described [56].
Figure 9. Proposed model for TBX2 regulation of EMT. TGFß
signaling, or amplification of human chromosomal region 17q23 lead to
aberrant TBX2 expression in differentiated breast epithelial cells, which
normally lack TBX2 expression. TBX2 directly represses transcription of
the epithelial differentiation marker E-cadherin and downregulates
other epithelial markers. In contrast, TBX2 induces expression of
mesenchymal markers, thereby resulting in EMT and invasion of normal
and malignant breast epithelial cells.
doi:10.1371/journal.pone.0041355.g009
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All human breast carcinoma cell lines, except the SUM lines
(Asterand), were from ATCC and cultured according to the
distributors’ recommendations. Specifically, MDA-MB-435 and
MDA-MB-157 cells were grown in DMEM plus 10% FBS and
1% Penicillin-Streptomycin, hereafter referred to as complete
growth medium. All cell lines were maintained in a 5% CO2-
humidified incubator at 37uC.
Western Blot Analysis
Immunoblotting used 20 mg of total cell extracts and was
performed as described [86]. Primary antibodies were to TBX2
1:1,000 (sc-17880x; Santa Cruz Biotechnology), E-cadherin
1:1,000 (610181; BD Biosciences), ß-catenin 1:500 (610153; BD),
vimentin 1:2,000 (VIM 13.2; Sigma), N-cadherin 1:1,000 (610920;
BD), or ß-actin 1:10,000 (AC-15; Sigma). Secondary antibodies
were HRP-conjugated anti-goat and anti-mouse IgG (Invitrogen).
Protein bands were detected by enhanced chemiluminescence
using the Femto Western Blot kit (Pierce). Densitometry to
quantify protein expression levels was performed using ImageJ
software (NCBI).
Immunofluorescence
Fluorescence immunocytochemistry on cultured cells was
performed as previously described [56]. Primary antibodies were
to TBX2 (1:200; AB4147; Upstate-Millipore), E-cadherin (1:1,000;
BD), ß-catenin (1:200; BD), ZO1 (1:500; 61–7300; Zymed), N-
cadherin (1:500; BD), vimentin (1:500; Sigma), followed by
incubation with Alexa Fluor 488- or Alexa Fluor 594-conjugated
secondary antibodies (1:200; Invitrogen). Nuclei were stained with
50 mg/ml Hoechst 33258 (Sigma) in PBS and cells were visualized
on a Leitz Axiovert microscope after mounting in Prolong Gold
anti-fade reagent (Invitrogen).
Quantitative Real-Time PCR (qPCR)
qPCR analysis was performed as previously described [56,86]
using SYBR Green PCR Master Mix (New England Biolabs) and
a CFX96 Real Time PCR thermocycler (Biorad). Sequences of
qPCR primers are shown in Table S1. Triplicate samples were
performed and average Ct values were normalized to the values of
GAPDH.
In vitro Scratch Assay
Scratch assays were performed as described [87] with the
following modifications. 16106 cells were plated on a 60 mm dish
and cultured in complete growth media 24 h before the assay.
When cells reached confluence, a p200 pipette tip was used to
scrape a straight line through the cell monolayer. Cells were
washed once with growth medium to remove cell debris and to
smoothen the edge of the scratch. The culture medium was then
replaced with growth medium with a lower FBS content (5% FBS)
to minimize cell proliferation during the duration of the assay.
Images were taken at different time points after scratch on a Leica
DMIL inverted microscope using a Q-Imaging digital camera
(Micropublisher) and analyzed using ImageJ software (NCBI).
Acquisition of same field images was achieved by making reference
points using an ultra fine tip marker.
Transwell Migration and Matrigel Invasion Assays
Cells (1–26104) were resuspended in 100 ml of serum-free
growth medium and plated into uncoated or Matrigel-coated 8-
mm transwell filter inserts (Corning) of 24-well plates in triplicates.
For invasion assays, filters were pre-coated with 10 ml of matrigel
(BD) diluted 1:4 in ice-cold serum-free medium and allowed to
solidify for 1 h at 37uC before use. The bottom wells contained
500 ml of growth medium with 10% FBS as chemoattractant.
After incubation of cells for 16 h for migration or for 48 h for
invasion assays, cells on the upper surface of the filter were
removed with a cotton swab and cells on the bottom side were
fixed in 100% methanol and stained with 1% Toluidine Blue in
1% Borax. Cells were counted in three random fields on
microscopic images taken at 10x or 40x magnification.
RNAi, Lentiviral shRNA Transduction
HC11+TBX2 murine mammary epithelial and human MDA-
MB-157 breast tumor cells were transiently transfected with
scrambled control or TBX2 gene-specific Smartpool siRNAs
(Dharmacon) at a final concentration of 100 nM using Dharma-
fect #1 transfection reagent according to manufacturer’s protocol.
Changes in EMT marker expression and cell motility/invasion
were evaluated 3–4 days post siRNA transfection. For stable
TBX2 knockdown, MDA-MB-435 cells were initially transduced
with 5 different TBX2-specific shRNAs (Mission shRNA lentiviral
particles; Sigma, TRCN0000232146-150) or control non-target
shRNA (Sigma, SHC002V) at MOI= 5. TBX2 shRNA
TRCN0000232147 (59CCGGTGAGATGCCCAAACGCATG-
TACTCGAGTACATGCGTTTGGGCATCTCATTTTTG-39)
yielded the highest TBX2 knockdown efficiency in qPCR and WB
analysis and was used to generate stable TBX2 knockdown cells.
Individual MDA-MB-435 cell clones stably expressing TBX2
shRNA or control shRNA were obtained by selection in 1 mg/ml
puromycin for 10 days.
3-D Matrigel Assays
Single cell suspensions of 26104 MDA-MB-435 cells in 100 ml
of complete growth media containing ice cold Matrigel (BD) (1:1)
were plated in triplicates on a 96-well plate. Plates were incubated
at 5% CO2, 37uC for 30 min to allow the matrigel to solidify, after
which 100 ml of complete media was added to each well. The
culture media was changed every 3 days. Ten to 14 days after
plating, pictures were taken under bright field at 20X magnifica-
tion using a Leica DMIL inverted microscope.
Tail Vein Metastasis Assays
Six week-old Nude (nu/nu) mice (Charles River Laboratories)
were inoculated with 16106 MDA-MB-435 tumor cells/mouse (in
150 ml of PBS) via tail vein injection. Forty days after tumor cell
inoculation, animals were euthanized, and lungs were inflated with
India ink, as described [88]. Surface lung nodules and micro-
metastases were scored in a genotype-blinded fashion using a Leica
MZ16 stereomicroscope. Lungs were then paraffin-embedded,
and 5 mM sections were stained with hematoxylin-eosin.
Cell Proliferation Assays
MDA-MBA-435 cells (1.56105) were seeded in triplicates on 12
well plates on day 0. Cells were grown under subconfluent
conditions in complete growth medium containing 1 mg/ml
puromycin and split at a ratio of 1:3 every 3 days. Cell numbers
were counted at the time of passaging over a total period of 9 days.
Chromatin Immunoprecipitation (ChIP)
Cells were grown to 80% confluence and cross-linked with 1%
formaldehyde at RT for 10 min. ChIP assays were performed as in
[86], except that sonication of cell lysates was performed for 15
pulses of 10 sec with 1 min interval each on ice at 20% power on
a Misonix sonicator. Sheared chromatin was immunoprecipitated
with 5 mg of antibodies to TBX2 (AB4147; Upstate-Millipore and
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sc-17880x; Santa Cruz), anti-acetyl Histone 3, or normal rabbit
IgG (Upstate-Millipore). PCR primers for amplification of
different regions of the mouse E-cadherin/Cdh1 promoter are listed
in Table S1.
Luciferase Reporter Assays
HC11 were seeded in 12-well tissue culture plates at a density of
26105 the day prior to transfection. Cells were cotransfected using
Lipofectamine 2000 (Invitrogen) with 500 ng of pCDNA3 or
pCDNA3-TBX2 expression vectors, 500 ng of pGL2Basic-
EcadK1 luciferase reporter construct (containing wild type human
E-Cadherin/CDK1 promoter sequences from 2108 to +125/
Addgene) [70], and 25 ng of pRL-CMV Renilla plasmid
(Promega), which served as normalization control. Forty-eight
hours after transfection, cells were harvested and subjected to
a Promega Dual Luciferase assay using a Veritas Luminometer.
Analysis of Published Gene Expression Datasets
Microarray data representing a total of 1107 primary breast
tumors from six previously published Affymetrix studies were
downloaded from repositories (E-TABM-158, GSE7390,
GSE4922, GSE1456, GSE2990, GSE2034) and integrated as
described previously using a mean-batch centering method [57].
The NKI [66] and [61] datasets were retrieved from http://
microarray-pubs.stanford.edu/would_NKI/explore.html and
NCBI GEO (GSE10885). The x-tile method was used to
determine the optimal cut-point in Kaplan Meier analysis while
correcting for the use of minimum P statistics [89].
Statistical Analysis
All other data represented in graphs were analyzed by two-sided
Student’s t or ANOVA tests using GraphPad Prism software. P-
values of ,0.05 were considered significant.
Supporting Information
Figure S1 Ectopic TBX2 induces EMT of MCF10A
mammary epithelial cells. (A) Immunofluorescence analysis
of EMT marker expression (40X magnification) shows a reduction
and loss of membrane-associated expression of epithelial (green)
markers (E-cadherin, ß-catenin, ZO1) with a concomitant gain of
mesenchymal (red) marker (N-Cadherin, Vimentin) expression in
MCF10A cells stably expressing pCDNA3-TBX2 (+TBX2) as
compared to cells expressing pCDNA3 vector (+vector) only. (B)
qPCR analysis of TBX2 and EMT marker gene expression using
cDNA from the same cells as in (A). Values were normalized to
GAPDH and fold changes are compared to vector control. The
mean 6 SEM is shown (n= 3; Student t-test). P- values: *p,0.05.
(TIF)
Figure S2 TBX2 expression in published microarray
datasets of primary human breast cancers. Gene profiling
expression data for TBX2 classified by (A) intrinsic molecular
subtypes; (B) Estrogen Receptor alpha (ER) status, as determined
by immunohistochemistry; and (C) histological grade, in 1107
tumors from six combined published microarray datasets [57]. (D)
TBX2 expression in the Hennessy et al. dataset comprising 219
tumors including aggressive metaplastic breast tumors [59,60,61].
The number of samples in each class and p-values are indicated.
NS = not significant; v = versus.
(TIF)
Figure S3 Expression and gene amplification of TBX2
in human breast cancer cell lines. (A–C) Tumor lines are
grouped into luminal and basal tumor subtypes according to Neve
et al. [90]. (A) Western blot analysis confirms TBX2 protein
expression in breast cancer cell lines with known TBX2 gene
amplification (open triangle): the luminal Estrogen Receptor
(ER)2positive (+) lines MCF7, MDA-MB-361, and BT474; and
the basal subtype ER-negative (underlined) breast tumor cell line
SUM52. Note that SUM52 is listed as luminal ER+ in the Neve
et al. dataset [90] but has been re-classified as basal-subtype triple-
negative [62]. Furthermore, TBX2 is overexpressed in the highly
invasive basal subgroup metaplastic breast tumor cell lines MDA-
MB-157, MDA-MB-435, and weakly in basal subgroup medullary
(asterix) HCC1569 tumor cells. (B) qPCR analysis quantifies TBX2
mRNA expression levels in the tumor cell lines shown in (A).
Values were normalized to GAPDH mRNA levels and represent
fold change as compared to normal human mammary epithelial
cells (HMEC). Error bars represent the mean 6 SEM (n= 3;
Student t-test). (C) Comparative genomic hybridization array
(aCGH) analysis shows relative gains and losses of the chromo-
somal region of TBX2 (17q23) in the selected breast cancer cell
lines from two published aCGH studies. Dark grey = [90]; light
grey = [91]. Not all cell lines were represented in both studies,
however the relative gains/losses for the TBX2 region between the
two studies was significantly correlated (Pearson, R=0.6,
p = 0.001) across the overlapping breast tumor cell lines.
(TIF)
Figure S4 Absence of TBX2 expression in existing
BRCA1-deficient breast carcinoma cell lines. (A) Western
blot analysis of endogenous TBX2 protein expression in four
BRCA12/2 breast carcinoma cell lines [92], as indicated. (B)
Comparative genomic hybridization array (aCGH) analysis shows
no consistent relative gains of the chromosomal region of TBX2
(17q23) in the selected BRCA12/2 breast cancer cell lines from two
published aCGH studies (Pearson, R= 0.6, p = 0.001). Dark grey
= [90]; light grey = [91].
(TIF)
Figure S5 Reciprocal expression of TBX2 and TBX3 in
normal and neoplastic breast epithelial cell lines. (A)
qPCR analysis of Tbx2 and Tbx3 mRNA expression in
HC11+vector and HC11+TBX2 cells, and in HC11+TBX2 cells
transiently transfected with scrambled siRNAs (siCtrl) or TBX2
siRNAs (siTBX2) three days post siRNA transfection. Note that, in
contrast to TBX2, TBX3 is abundantly expressed in control HC11-
vector (+vector) cells. Ectopic expression of TBX2 in HC11 cells
(+TBX2) leads to a marked reduction in Tbx3mRNA levels, which
is reversed by knockdown of exogenous TBX2. (B) qPCR analysis
of MDA-MB-435 tumor cells stably expressing non-target control
shRNA (shCtrl) or TBX2-specific shRNA (shTBX2) shows low
levels of TBX3 mRNA in endogenously TBX2-overexpressing
MDA-MB-435 control cells and upregulation of TBX3 upon
TBX2 knockdown. Values were normalized to GAPDH. The mean
6 SEM is shown (n= 3; Student t-test).
(TIF)
Table S1 List of oligonucleotide sequences separated by
assay type.
(DOC)
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